Top

Published in:

Open Access 01-03-2025 | Gene Therapy | REVIEW

Advancements in gene therapies targeting mutant KRAS in cancers

Authors: Yuhang Wang, Thuy Anh Bui, Xinpu Yang, Gyorgy Hutvagner, Wei Deng

Published in: Cancer and Metastasis Reviews | Issue 1/2025

Abstract

Mutations in the KRAS gene are well-known tumourigenic drivers of colorectal, pancreatic and lung cancers. Mechanistically, these mutations promote uncontrolled cell proliferation and alter the tumour microenvironment during early carcinoma stages. Given their critical carcinogenic functions, significant progress has been made in developing KRAS inhibitors for cancer treatment. However, clinical applications of these KRAS inhibitor compounds are limited to specific cancer types which carry the relevant KRAS mutations. Additionally, clinical findings have shown that these compounds can induce moderate to serious side effects. Therefore, new approaches have emerged focusing on the development of universal therapeutics capable of targeting a wider range of KRAS mutations, minimising toxicity and enhancing the therapeutic efficacy. This review aims to examine these therapeutic strategies in the context of cancer treatment. It firstly provides an overview of fundamental KRAS biology within the cell signalling landscape and how KRAS mutations are associated with cancer pathogenesis. Subsequently, it introduces the development of current KRAS inhibitors which target certain KRAS mutants in different types of cancer. It then explores the potential of gene therapy approaches, including siRNA, miRNA and CRISPR methodologies. Furthermore, it discusses the use of lipid-based nanocarriers to deliver gene cargos for targeting KRAS gene mutants. Finally, it provides the insights into the future prospects for combatting KRAS mutation-associated cancers.

Graphical Abstract

Barbacid, M. (1987). Ras genes. Annual Review of Biochemistry, 56, 779–827. https://doi.org/10.1146/annurev.bi.56.070187.004023FromNLMMedlineCrossRefPubMed

Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: From undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 6(1), 386. https://doi.org/10.1038/s41392-021-00780-4FromNLMMedlineCrossRefPubMedPubMedCentral

Karnoub, A. E., & Weinberg, R. A. (2008). Ras oncogenes: Split personalities. Nature Reviews Molecular Cell Biology, 9(7), 517–531. https://doi.org/10.1038/nrm2438FromNLMMedlineCrossRefPubMedPubMedCentral

Santos, E., & Nebreda, A. R. (1989). Structural and functional properties of ras proteins. The FASEB Journal, 3(10), 2151–2163. https://doi.org/10.1096/fasebj.3.10.2666231FromNLMMedlineCrossRefPubMed

Vetter, I. R., & Wittinghofer, A. (2001). The guanine nucleotide-binding switch in three dimensions. Science, 294(5545), 1299–1304. https://doi.org/10.1126/science.1062023FromNLMMedlineCrossRefPubMed

Takai, Y., Sasaki, T., & Matozaki, T. (2001). Small GTP-binding proteins. Physiological Reviews, 81(1), 153–208. https://doi.org/10.1152/physrev.2001.81.1.153FromNLMMedlineCrossRefPubMed

Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007). GEFs and GAPs: Critical elements in the control of small G proteins. Cell, 129(5), 865–877. https://doi.org/10.1016/j.cell.2007.05.018FromNLMMedlineCrossRefPubMed

Iversen, L., Tu, H. L., Lin, W. C., Christensen, S. M., Abel, S. M., Iwig, J., & Wu, H. J. (2014). Gureasko, J.; Rhodes, C.; Petit, R. S.; et al. Molecular kinetics. Ras activation by SOS: allosteric regulation by altered fluctuation dynamics. Science, 345 (6192), 50–54. https://doi.org/10.1126/science.1250373 From NLM Medline.

Voldborg, B. R., Damstrup, L., Spang-Thomsen, M., & Poulsen, H. S. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8(12), 1197–1206. https://doi.org/10.1023/a:1008209720526FromNLMMedlineCrossRef

10.

Brambilla, R., Gnesutta, N., Minichiello, L., White, G., Roylance, A. J., Herron, C. E., Ramsey, M., Wolfer, D. P., Cestari, V., Rossi-Arnaud, C., et al. (1997). A role for the Ras signalling pathway in synaptic transmission and long-term memory. Nature, 390(6657), 281–286. https://doi.org/10.1038/36849FromNLMMedlineCrossRefPubMed

11.

Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Gorgulu, K., Dantes, Z., Wormann, S. M., Diakopoulos, K. N., et al. (2018). Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nature Medicine, 24(7), 954–960. https://doi.org/10.1038/s41591-018-0024-8FromNLMMedlineCrossRefPubMed

12.

Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z. Y., Zadeh, G., & Ohh, M. (2015). Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Communications, 6, 8859. https://doi.org/10.1038/ncomms9859FromNLMMedlineCrossRefPubMed

13.

Dance, M., Montagner, A., Salles, J. P., Yart, A., & Raynal, P. (2008). The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cellular Signalling, 20(3), 453–459. https://doi.org/10.1016/j.cellsig.2007.10.002FromNLMMedlineCrossRefPubMed

14.

Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002). Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nature Cell Biology, 4(11), 850–858. https://doi.org/10.1038/ncb867FromNLMMedlineCrossRefPubMed

15.

Gualdrini, F., Esnault, C., Horswell, S., Stewart, A., Matthews, N., & Treisman, R. (2016). SRF co-factors control the balance between cell proliferation and contractility. Molecular Cell, 64(6), 1048–1061. https://doi.org/10.1016/j.molcel.2016.10.016FromNLMMedlineCrossRefPubMedPubMedCentral

16.

Liu, R. Y., Zhang, Y., Smolen, P., Cleary, L. J., & Byrne, J. H. (2020). Role of p90 ribosomal S6 kinase in long-term synaptic facilitation and enhanced neuronal excitability. Science and Reports, 10(1), 608. https://doi.org/10.1038/s41598-020-57484-yFromNLMMedlineCrossRef

17.

Liu, G. Y., & Sabatini, D. M. (2020). mTOR at the nexus of nutrition, growth, ageing and disease. Nature Reviews Molecular Cell Biology, 21(4), 183–203. https://doi.org/10.1038/s41580-019-0199-yFromNLMMedlineCrossRefPubMedPubMedCentral

18.

Tomasini, P., Walia, P., Labbe, C., Jao, K., & Leighl, N. B. (2016). Targeting the KRAS pathway in non-small cell lung cancer. The Oncologist, 21(12), 1450–1460. https://doi.org/10.1634/theoncologist.2015-0084FromNLMMedlineCrossRefPubMedPubMedCentral

19.

Schubbert, S., Shannon, K., & Bollag, G. (2007). Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer, 7(4), 295–308. https://doi.org/10.1038/nrc2109FromNLMMedlineCrossRefPubMed

20.

Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010). Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? Nature Reviews Cancer, 10(12), 842–857. https://doi.org/10.1038/nrc2960FromNLMMedlineCrossRefPubMedPubMedCentral

21.

Zhou, B., Der, C. J., & Cox, A. D. (2016). The role of wild type RAS isoforms in cancer. Seminars in Cell & Developmental Biology, 58, 60–69. https://doi.org/10.1016/j.semcdb.2016.07.012CrossRef

22.

Singh, A., Sowjanya, A. P., & Ramakrishna, G. (2005). The wild-type Ras: Road ahead. The FASEB Journal, 19(2), 161–169. https://doi.org/10.1096/fj.04-2584hypCrossRefPubMed

23.

Prior, I. A., Lewis, P. D., & Mattos, C. (2012). A comprehensive survey of Ras mutations in cancer. Cancer Research, 72(10), 2457–2467.CrossRefPubMedPubMedCentral

24.

Kimura, K., Nagasaka, T., Hoshizima, N., Sasamoto, H., Notohara, K., Takeda, M., Kominami, K., Iishii, T., Tanaka, N., & Matsubara, N. (2007). No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. Journal of International Medical Research, 35(4), 450–457.CrossRefPubMed

25.

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., & Johnson, D. H. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23(25), 5900–5909.CrossRefPubMed

26.

Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021). Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol, 12(4), 217–237. https://doi.org/10.5306/wjco.v12.i4.217FromNLMCrossRefPubMedPubMedCentral

27.

Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011). RAS oncogenes: Weaving a tumorigenic web. Nature Reviews Cancer, 11(11), 761–774.CrossRefPubMedPubMedCentral

28.

Dias Carvalho, P., Guimaraes, C. F., Cardoso, A. P., Mendonca, S., Costa, A. M., Oliveira, M. J., & Velho, S. (2018). KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer research, 78(1), 7–14.CrossRefPubMed

29.

Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016). Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. In: Seminars in cell & developmental biology, Elsevier: Vol. 58, pp 127–135.

30.

Golay, H. G., & Barbie, D. A. (2014). Targeting cytokine networks in KRAS-driven tumorigenesis. Taylor & Francis, 14, 869–871.

31.

Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & Di Magliano, M. P. (2013). Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer research, 73(20), 6359–6374.CrossRefPubMed

32.

Sparmann, A., & Bar-Sagi, D. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell, 6(5), 447–458.CrossRefPubMed

33.

Sunaga, N., Imai, H., Shimizu, K., Shames, D. S., Kakegawa, S., Girard, L., Sato, M., Kaira, K., Ishizuka, T., & Gazdar, A. F. (2012). Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. International Journal of Cancer, 130(8), 1733–1744.CrossRefPubMed

34.

Lee, J. W., Zhang, Y., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E., et al. (2019). The combination of MEK Inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras/p53-driven lung cancer. Journal of Thoracic Oncology, 14(6), 1046–1060. https://doi.org/10.1016/j.jtho.2019.02.004FromNLMCrossRefPubMedPubMedCentral

35.

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 503(7477), 548–551. https://doi.org/10.1038/nature12796FromNLMCrossRefPubMedPubMedCentral

36.

Ostrem, J. M., & Shokat, K. M. (2016). Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design. Nature Reviews. Drug Discovery, 15(11), 771–785. https://doi.org/10.1038/nrd.2016.139FromNLMMedlineCrossRefPubMed

37.

Liu, J., Kang, R., & Tang, D. (2022). The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Therapy, 29(7), 875–878. https://doi.org/10.1038/s41417-021-00383-9CrossRefPubMed

38.

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., & Koppada, N. (2019). The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217–223.CrossRefPubMed

39.

Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., & Ngang, J. (2019). Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. American Society of Clinical Oncology.

40.

de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M.C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., & Skoulidis, F. (2023). Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. The Lancet, 401(10378), 733–746.CrossRef

41.

Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., & Burkard, M. R. (2020). Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. Journal of Medicinal Chemistry, 63(13), 6679–6693.CrossRefPubMed

42.

Jänne, P., Rybkin, I. I., Spira, A., Riely, G., Papadopoulos, K., Sabari, J., Johnson, M., Heist, R., Bazhenova, L., & Barve, M. (2020). KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in advanced/metastatic non–small-cell lung cancer (NSCLC) harboring KRAS G12C mutation. European Journal of Cancer, 138, S1–S2.CrossRef

43.

Zhang, J., Leventakos, K., Leal, T., Pennell, N., Barve, M., Paulson, A., Bazhenova, L., Johnson, M., Chao, R., & Velastegui, K. (2022). 1133P Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC. Annals of Oncology, 33, S1068–S1069.CrossRef

44.

Zhang, J., Johnson, M., Barve, M., Bazhenova, L., McCarthy, M., Schwartz, R., Horvath-Walsh, E., Velastegui, K., Qian, C., & Spira, A. (2023). Practical guidance for the management of adverse events in patients with KRASG12C-mutated non-small cell lung cancer receiving adagrasib. The Oncologist, 28(4), 287–296.CrossRefPubMedPubMedCentral

45.

Food, U. (2022). Administration, D. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC.

46.

Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022). The path to the clinic: A comprehensive review on direct KRASG12C inhibitors. Journal of Experimental & Clinical Cancer Research, 41(1), 1–23.CrossRef

47.

Peng, S.-B., Si, C., Zhang, Y., Van Horn, R. D., Lin, X., Gong, X., Huber, L., Donoho, G., Curtis, C., & Strelow, J. M. (2021). Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Cancer Research, 81 (13_Supplement), 1259–1259.

48.

Murciano-Goroff, Y. R., Heist, R. S., Kuboki, Y., Koyama, T., Ammakkanavar, N. R., Hollebecque, A., Patnaik, A., Shimizu, T., Spira, A. I., & Nagasaka, M. (2023). Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Cancer Research, 83 (8_Supplement), CT028-CT028.

49.

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Jr., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., & Paz-Ares, L. (2023). Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. New England Journal of Medicine, 389(8), 710–721.CrossRefPubMed

50.

Shi, Z., Weng, J., Fan, X., Wang, E., Zhu, Q., Tao, L., Han, Z., Wang, Z., Niu, H., & Jiang, Y. (2021). Discovery of D-1553, a novel and selective KRas-G12C inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models. Cancer Research, 81 (13_Supplement), 932–932.

51.

Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., & Zhuang, W. (2023). D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: Phase 1 study results. Journal of Thoracic Oncology, 18(7), 940–951.CrossRefPubMed

52.

Sakamoto, K., Kamada, Y., Sameshima, T., Yaguchi, M., Niida, A., Sasaki, S., Miwa, M., Ohkubo, S., Sakamoto, J.-I., & Kamaura, M. (2017). K-Ras (G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. Biochemical and Biophysical Research Communications, 484(3), 605–611.CrossRefPubMed

53.

Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M., Yonemori, K., Sasaki, S., Sakamoto, J.-I., & Sakamoto, K. (2017). Crystal structure of a human K-Ras G12D mutant in complex with GDP and the cyclic inhibitory peptide KRpep-2d. ACS medicinal Chemistry Letters, 8(7), 732–736.CrossRefPubMedPubMedCentral

54.

Sakamoto, K., Masutani, T., & Hirokawa, T. (2020). Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity In vivo. Scientific Reports, 10(1), 21671. https://doi.org/10.1038/s41598-020-78712-5CrossRefPubMedPubMedCentral

55.

Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., & Lifset, E. (2022). Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 28(10), 2171–2182.CrossRefPubMed

56.

Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023). Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discovery, 13(2), 298–311. https://doi.org/10.1158/2159-8290.Cd-22-1066. (acccessed1/23/2024).CrossRefPubMed

57.

Teng, K. W., Tsai, S. T., Hattori, T., Fedele, C., Koide, A., Yang, C., Hou, X., Zhang, Y., Neel, B. G., O’Bryan, J. P., et al. (2021). Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nature Communications, 12(1), 2656. https://doi.org/10.1038/s41467-021-22969-5CrossRefPubMedPubMedCentral

58.

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K. K. (2022). The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews. Clinical Oncology, 19(10), 637–655. https://doi.org/10.1038/s41571-022-00671-9FromNLMMedlineCrossRefPubMedPubMedCentral

59.

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022). Drug delivery systems for RNA therapeutics. Nature Reviews Genetics, 23(5), 265–280. https://doi.org/10.1038/s41576-021-00439-4FromNLMMedlineCrossRefPubMedPubMedCentral

60.

Karimi, M., Ghasemi, A., Zangabad, P. S., Rahighi, R., Basri, S. M. M., Mirshekari, H., Amiri, M., Pishabad, Z. S., Aslani, A., & Bozorgomid, M. (2016). Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chemical Society Reviews, 45(5), 1457–1501.CrossRefPubMedPubMedCentral

61.

Anthiya, S., Öztürk, S. C., Yanik, H., Tavukcuoglu, E., Şahin, A., Datta, D., Charisse, K., Álvarez, D. M., Loza, M. I., Calvo, A., et al. (2023). Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. Journal of Controlled Release, 357, 67–83. https://doi.org/10.1016/j.jconrel.2023.03.016CrossRefPubMed

62.

Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015). RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget, 6(27), 24560–24570. https://doi.org/10.18632/oncotarget.4183FromNLMMedlineCrossRefPubMedPubMedCentral

63.

Huang, R., Du, H., Cheng, L., Zhang, P., Meng, F., & Zhong, Z. (2023). Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer. Acta Biomaterialia, 168, 529–539. https://doi.org/10.1016/j.actbio.2023.07.008CrossRefPubMed

64.

Cullis, P. R., & Felgner, P. L. (2024). The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nature Reviews Drug Discovery, 23(9), 709–722. https://doi.org/10.1038/s41573-024-00977-6FromNLMCrossRefPubMed

65.

Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology, 13 (1), 238-IN227.

66.

Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug discovery, 4(2), 145–160.CrossRefPubMed

67.

Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020). Liposomes: Advancements and innovation in the manufacturing process. Advanced Drug Delivery Reviews, 154–155, 102–122. https://doi.org/10.1016/j.addr.2020.07.002FromNLMMedlineCrossRefPubMed

68.

Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3), 297.PubMedPubMedCentral

69.

Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, O. r., & Sahay, G. (2017). Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Letters, 17 (9), 5711–5718.

70.

Zhen, S., Qiang, R., Lu, J., Tuo, X., Yang, X., & Li, X. (2023). CRISPR/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer. Journal of Medical Virology, 95(1), e28144.CrossRefPubMed

71.

del Pozo-Rodriguez, A., Solinís, M. Á., & Rodríguez-Gascón, A. (2016). Applications of lipid nanoparticles in gene therapy. European Journal of Pharmaceutics and Biopharmaceutics, 109, 184–193.CrossRefPubMed

72.

Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., & Heldman, E. (2009). Blumenthal, R. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Critical Reviews™ in Therapeutic Drug Carrier Systems, 26 (6).

73.

Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Kumar, N. S., & Vekariya, R. L. (2020). A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Advances, 10(45), 26777–26791.CrossRefPubMedPubMedCentral

74.

Swathi, G., Prasanthi, N., Manikiran, S., & Ramarao, N. (2012). Solid lipid nanoparticles: colloidal carrier systems for drug delivery. ChemInform, 43 (2), no.

75.

Oner, E., Kotmakci, M., Baird, A.-M., Gray, S. G., Debelec Butuner, B., Bozkurt, E., Kantarci, A. G., & Finn, S. P. (2021). Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. Journal of Nanobiotechnology, 19(1), 1–20.CrossRef

76.

Geszke-Moritz, M., & Moritz, M. (2016). Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Materials Science and Engineering: C, 68, 982–994.CrossRefPubMed

77.

Araujo, V. H. S., Delello Di Filippo, L., Duarte, J. L., Sposito, L., Camargo, B. A. F. d., da Silva, P. B., & Chorilli, M. (2021). Exploiting solid lipid nanoparticles and nanostructured lipid carriers for drug delivery against cutaneous fungal infections. Critical reviews in Microbiology, 47 (1), 79–90.

78.

Hao, J., Wang, F., Wang, X., Zhang, D., Bi, Y., Gao, Y., Zhao, X., & Zhang, Q. (2012). Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. European Journal of Pharmaceutical Sciences, 47(2), 497–505.CrossRefPubMed

79.

Zhang, L., Chan, J. M., Gu, F. X., Rhee, J.-W., Wang, A. Z., Radovic-Moreno, A. F., Alexis, F., Langer, R., & Farokhzad, O. C. (2008). Self-assembled lipid− polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano, 2(8), 1696–1702.CrossRefPubMedPubMedCentral

80.

Hadinoto, K., Sundaresan, A., & Cheow, W. S. (2013). Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. European Journal of Pharmaceutics and Biopharmaceutics, 85(3), 427–443.CrossRefPubMed

81.

Colombo, S., Cun, D., Remaut, K., Bunker, M., Zhang, J., Martin-Bertelsen, B., Yaghmur, A., Braeckmans, K., Nielsen, H. M., & Foged, C. (2015). Mechanistic profiling of the siRNA delivery dynamics of lipid–polymer hybrid nanoparticles. Journal of Controlled Release, 201, 22–31.CrossRefPubMed

82.

Li, Z., Zhang, X. Q., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., & Zhu, H. (2022). Lipid-polymer hybrid “particle-in-particle” nanostructure gene delivery platform explored for lyophilizable DNA and mRNA COVID-19 vaccines. Advanced Functional Materials, 32(40), 2204462.CrossRefPubMedPubMedCentral

83.

Zheng, X., Luo, J., Liu, W., Ashby Jr, C. R., Chen, Z.-S., & Lin, L. (2022). Sotorasib: A treatment for non-small cell lung cancer with the KRAS G12C mutation. Drugs of Today (Barcelona, Spain: 1998), 58 (4), 175–185.

84.

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021). Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 20(1), 143. https://doi.org/10.1186/s12943-021-01441-4CrossRefPubMedPubMedCentral

85.

Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes & Development, 15(2), 188–200. https://doi.org/10.1101/gad.862301FromNLMCrossRef

86.

Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. m. M., Aljabali, A. A. A., & Awidi, A. (2021). siRNA: Mechanism of action, challenges, and therapeutic approaches. European Journal of Pharmacology, 905, 174178. https://doi.org/10.1016/j.ejphar.2021.174178.

87.

Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019). Strategies, design, and chemistry in siRNA delivery systems. Advanced Drug Delivery Reviews, 144, 133–147. https://doi.org/10.1016/j.addr.2019.05.004FromNLMCrossRefPubMedPubMedCentral

88.

Rossi, J. J., & Rossi, D. J. (2021). siRNA drugs: Here to stay. Molecular Therapy, 29(2), 431–432. https://doi.org/10.1016/j.ymthe.2021.01.015FromNLMMedlineCrossRefPubMedPubMedCentral

89.

Turner, J. J., Jones, S. W., Moschos, S. A., Lindsay, M. A., & Gait, M. J. (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Molecular BioSystems, 3(1), 43–50. https://doi.org/10.1039/B611612D.DOI:10.1039/B611612D

90.

Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009). A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Research, 37(9), 2867–2881. https://doi.org/10.1093/nar/gkp106(acccessed5/8/2024)CrossRefPubMedPubMedCentral

91.

Musacchio, T., Vaze, O., D’Souza, G., & Torchilin, V. P. (2010). Effective stabilization and delivery of siRNA: Reversible siRNA−phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjugate Chemistry, 21(8), 1530–1536. https://doi.org/10.1021/bc100199cCrossRefPubMed

92.

Perepelyuk, M., Shoyele, O., Birbe, R., Thangavel, C., Liu, Y., Den, R. B., Snook, A. E., Lu, B., & Shoyele, S. A. (2017). siRNA-encapsulated hybrid nanoparticles target mutant K-ras and inhibit metastatic tumor burden in a mouse model of lung cancer. Mol Ther Nucleic Acids, 6, 259–268. https://doi.org/10.1016/j.omtn.2016.12.009FromNLMCrossRefPubMed

93.

Varghese, A. M., Ang, C., Dimaio, C. J., Javle, M. M., Gutierrez, M., Yarom, N., Stemmer, S. M., Golan, T., Geva, R., Semenisty, V., et al. (2020). A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). Journal of Clinical Oncology, 38 (15_suppl), TPS4672-TPS4672. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS4672.

94.

Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., et al. (2021). Silencing of oncogenic KRAS by mutant-selective small interfering RNA. ACS Pharmacol Transl Sci, 4(2), 703–712. https://doi.org/10.1021/acsptsci.0c00165FromNLMPubMed-not-MEDLINECrossRefPubMedPubMedCentral

95.

Parayath, N. N., Gandham, S. K., & Amiji, M. M. (2022). Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance. Nanomedicine (London, England), 17(19), 1355–1373. https://doi.org/10.2217/nnm-2022-0130FromNLMCrossRefPubMed

96.

Zhang, Z., Huang, Q., Yu, L., Zhu, D., Li, Y., Xue, Z., Hua, Z., Luo, X., Song, Z., Lu, C., et al. (2021). The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Frontiers in Immunology, 12, 807895. https://doi.org/10.3389/fimmu.2021.807895FromNLMCrossRefPubMed

97.

Lai, X., Eberhardt, M., Schmitz, U., & Vera, J. (2019). Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Research, 47(15), 7753–7766. https://doi.org/10.1093/nar/gkz638(acccessed3/13/2024)CrossRefPubMedPubMedCentral

98.

Bartel, D. P. (2018). Metazoan micrornas. Cell, 173(1), 20–51.CrossRefPubMedPubMedCentral

99.

Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6(4), 259–269.CrossRefPubMed

100.

Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., & Negrini, M. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences, 101(9), 2999–3004.CrossRef

101.

Ibrahim, H., & Lim, Y. C. (2020). KRAS-associated microRNAs in colorectal cancer. Oncology Reviews, 14(2), 454. https://doi.org/10.4081/oncol.2020.454FromNLMPubMed-not-MEDLINECrossRefPubMedPubMedCentral

102.

Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences, 101(9), 2999–3004. https://doi.org/10.1073/pnas.0307323101FromNLMCrossRef

103.

Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647. https://doi.org/10.1016/j.cell.2005.01.014FromNLMCrossRefPubMed

104.

Stahlhut, C., & Slack, F. J. (2015). Combinatorial action of MicroRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle, 14(13), 2171–2180. https://doi.org/10.1080/15384101.2014.1003008CrossRefPubMedPubMedCentral

105.

Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy, 19(6), 1116–1122. https://doi.org/10.1038/mt.2011.48FromNLMMedlineCrossRefPubMedPubMedCentral

106.

Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Lagana, A., Zanesi, N., Fadda, P., Fassan, M., Rizzotto, L., et al. (2017). Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci U S A, 114(21), E4203–E4212. https://doi.org/10.1073/pnas.1620562114FromNLMMedlineCrossRefPubMedPubMedCentral

107.

Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022). CRISPR in cancer biology and therapy. Nature Reviews Cancer, 22(5), 259–279. https://doi.org/10.1038/s41568-022-00441-wCrossRefPubMed

108.

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nature Protocols, 8(11), 2281–2308. https://doi.org/10.1038/nprot.2013.143CrossRefPubMedPubMedCentral

109.

Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096CrossRefPubMed

110.

Kim, W., Lee, S., Kim, H. S., Song, M., Cha, Y. H., Kim, Y. H., Shin, J., Lee, E. S., Joo, Y., Song, J. J., et al. (2018). Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Research, 28(3), 374–382. https://doi.org/10.1101/gr.223891.117CrossRefPubMedPubMedCentral

111.

Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018). Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Science and Reports, 8(1), 11879. https://doi.org/10.1038/s41598-018-30205-2CrossRef

112.

Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2020). Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression. Theranostics, 10(11), 5137–5153. https://doi.org/10.7150/thno.42325FromNLMMedlineCrossRefPubMedPubMedCentral

113.

Thakore, P. I., D’Ippolito, A. M., Song, L., Safi, A., Shivakumar, N. K., Kabadi, A. M., Reddy, T. E., Crawford, G. E., & Gersbach, C. A. (2015). Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods, 12(12), 1143–1149. https://doi.org/10.1038/nmeth.3630CrossRefPubMedPubMedCentral

114.

Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A.. et al. (2020). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances, 6 (47), eabc9450. https://doi.org/10.1126/sciadv.abc9450.

115.

Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017). KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunology, Immunotherapy, 66(9), 1175–1187. https://doi.org/10.1007/s00262-017-2005-zCrossRefPubMedPubMedCentral

116.

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., & Denlinger, C. S. (2020). KRASG12C inhibition with sotorasib in advanced solid tumors. New England Journal of Medicine, 383(13), 1207–1217.CrossRefPubMed

117.

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., & Barlesi, F. (2021). Sotorasib for lung cancers with KRAS p. G12C mutation. New England Journal of Medicine, 384 (25), 2371–2381.

118.

Seviour, E. G., Sehgal, V., Mishra, D., Rupaimoole, R., Rodriguez-Aguayo, C., Lopez-Berestein, G., Lee, J. S., Sood, A. K., Kim, M. P., Mills, G. B., et al. (2017). Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis In vivo by clinically significant miR-193a-3p. Oncogene, 36(10), 1339–1350. https://doi.org/10.1038/onc.2016.308CrossRefPubMed

119.

Wurm, A. A., Brilloff, S., Kolovich, S., Schafer, S., Rahimian, E., Kufrin, V., Bill, M., Carrero, Z. I., Drukewitz, S., Kruger, A., et al. (2023). Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. Cell Rep Med, 4(10), 101200. https://doi.org/10.1016/j.xcrm.2023.101200FromNLMMedlineCrossRefPubMedPubMedCentral

120.

Diener, C., Keller, A., & Meese, E. (2022). Emerging concepts of miRNA therapeutics: From cells to clinic. Trends in Genetics, 38(6), 613–626. https://doi.org/10.1016/j.tig.2022.02.006FromNLMMedlineCrossRefPubMed

121.

Sigoillot, F. D., & King, R. W. (2011). Vigilance and validation: Keys to success in RNAi screening. ACS Chemical Biology, 6(1), 47–60. https://doi.org/10.1021/cb100358fCrossRefPubMed

122.

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010). Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 28(2), 172–176. https://doi.org/10.1038/nbt.1602CrossRefPubMed

123.

Qin, J., Zhu, Y., Zheng, D., & Zhao, Q. (2021). pH-sensitive polymeric nanocarriers for antitumor biotherapeutic molecules targeting delivery. Bio-Design and Manufacturing, 4(3), 612–626. https://doi.org/10.1007/s42242-020-00105-4CrossRef

124.

Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020). Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nature Biotechnology, 38(7), 824–844.CrossRefPubMed

125.

Scholefield, J., & Harrison, P. T. (2021). Prime editing - An update on the field. Gene Therapy, 28(7–8), 396–401. https://doi.org/10.1038/s41434-021-00263-9CrossRefPubMedPubMedCentral

126.

Hassan, M. M., Yuan, G., Chen, J. G., Tuskan, G. A., & Yang, X. (2020). Prime editing technology and its prospects for future applications in plant biology research. Biodes Res, 2020, 9350905. https://doi.org/10.34133/2020/9350905CrossRefPubMedPubMedCentral

127.

Geurts, M. H., de Poel, E., Pleguezuelos-Manzano, C., Oka, R., Carrillo, L. Andersson-Rolf, A., Boretto, M., Brunsveld, J. E., van Boxtel, R., Beekman, J. M., et al. (2021). Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids. Life Sci Alliance, 4 (10). https://doi.org/10.26508/lsa.202000940.

128.

Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023). In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA. GEN Biotechnology, 2(6), 490–502. https://doi.org/10.1089/genbio.2023.0045CrossRef

Title: Advancements in gene therapies targeting mutant KRAS in cancers
Authors: Yuhang Wang
Thuy Anh Bui
Xinpu Yang
Gyorgy Hutvagner
Wei Deng
Publication date: 01-03-2025
Publisher: Springer US
Keywords: Gene Therapy
Targeted Therapy
NSCLC
Colorectal Cancer
Pancreatic Cancer
Published in: Cancer and Metastasis Reviews / Issue 1/2025
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-025-10243-9

Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions

Open Access
Osteosarcoma
Review

Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities

Open Access
Solid Tumor
Review

Neuropeptide Y in cancer—biological functions and potential clinical implications

Open Access
Metastasis
Review

Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art

Open Access
Radiotherapy
Review

Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies

SCLC
Review

The diversity of natural killer cell functional and phenotypic states in cancer

Review

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

12-12-2024
Lymphoma
News

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

12-12-2024
Mantle Cell Lymphoma
News

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

12-12-2024
Lymphoma
News

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Advancements in gene therapies targeting mutant KRAS in cancers

Abstract

Graphical Abstract

Other articles of this Issue 1/2025

Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions

Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities

Neuropeptide Y in cancer—biological functions and potential clinical implications

Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art

Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies

The diversity of natural killer cell functional and phenotypic states in cancer

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage